My Story
As you may know, I was diagnosed with ovarian cancer in 2024 and learned that I carry a BRCA2 genetic mutation, which puts both women and men—many don’t realize it affects men as well—at increased risk for several cancers.
If I had known beforehand, I would not be living the hell I am living today.
Through this experience, I became involved in research focused on hereditary cancer prevention—and learned that my daughter, Lucky, also carries this mutation.
Because of this knowledge, she now has the tools to protect her future in a way I did not.
About the IGNITE-TX Study
My oncologist at MD Anderson, in collaboration with Weill Cornell Medicine, is leading the IGNITE-TX study.
This research is focused on making genetic testing accessible to individuals at highest risk for hereditary cancer mutations—so they can understand their risk early and take action to prevent cancer before it develops.
Why This Matters
In a completed clinical trial:
- Up to 90% of at-risk relatives completed genetic testing when supported Compared to only 30% with standard approaches
- Half of those tested were found to carry BRCA1/2 mutation
This represents a major opportunity to prevent cancer through early awareness and intervention.
Funding Goal & Mission
We are currently working to raise $1 million dollars to expand the IGNITE-TX study nationally.
Our collective mission is simple:
Every person across this country should have access to genetic testing for hereditary cancer mutations. Together, we can prevent cancers before they begin.
Knowledge is power—and action changes outcomes.
Support This Work
If you would like to support this research, you can donate directly through MD Anderson here:
? Donate to IGNITE-TX Study
100% of donations go directly to MD Anderson Cancer Center research initiatives for this study.
Awareness looks good on everyone—but action can change lives.
Thank you for being part of this with me.
With gratitude,
Lori